#stankostrong…” On April 29, 2024, Jonathan Stanko received a diagnosis of stage four Adenocarcinoma gastric cancer. On May 10, 2024, he shared his journey in a blog post. Jonathan Stanko ...

Concordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samples. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...

Tevimbra, or tislelizumab-jsgr, is approved as a first-line treatment for adults suffering from a certain type of unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma ...

A Phase III clinical trial of cadonilimab combined with a VEGFR-2 monoclonal antibody for PD-1/L1 inhibitor-pretreated advanced gastric adenocarcinoma and gastroesophageal junction adenocarcinoma ...

Recognising the pressing need for new therapies, the FDA has already granted a fast-track designation to zolbetuximab for the treatment of gastric and GEJ adenocarcinoma. Other companies ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Role of intraperitoneal paclitaxel in eosinophil activation and recruitment in the peritoneal cavity and anti-tumor effects against peritoneal metastasis from gastric cancer. This is an ASCO Meeting ...

in combination with chemotherapy as a first-line option for certain forms of gastric or gastroesophageal carcinoma. Specifically, the anti-PD-1 monoclonal antibody will therefore be available in ...